Search Results
Srdan Verstovsek, ASH 2019: Individualized Management of Myeloproliferative neoplasms
Managing Myelofibrosis in 2021 - Dr. Srdan Verstovsek
Dr. Srdan Verstovsek on JAK2 Inhibitors as a Treatment for Myelofibrosis
Dr. Verstovsek on JAK Inhibition in Polycythemia Vera
Dr. Verstovsek Discusses Immunotherapy in Myelofibrosis
Targeted agents are desperately needed in myelofibrosis
What to look out for at ASH 2019: MPNs
Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs
Update on JAK2 Inhibitors by Srdan Verstovsek, MD
Abdulraheem Yacoub, ASH 2019: Novel Agents for the Treatment of PV and MF
Srdan Verstovsek, MD, PhD: Leukocytosis in PV
The Role of Ruxolitinib in Myeloproliferative Neoplasms
